Bayer cuts 227 jobs at Jivi plant in California

By Flora Southey

- Last updated on GMT

(Image: Getty/jarun011)
(Image: Getty/jarun011)

Related tags Bayer California

Having now secured regulatory approval for all three of its haemophilia A therapies made in Berkeley, Bayer is implementing “organisational changes” across the facility.

Last month, Bayer received regulatory approval for haemophilia A treatment, Jivi, in the US and Japan.

Haemophilia A is a genetic disorder caused by a missing or defective clotting protein, factor VIII.

Jivi is classified as a recombinant factor VIII (rFVIII) product and joins Bayer’s two rFVIII treatments already on the market – Kogenate and Kovaltry. Bayer manufactures all three treatments at the Californian facility.

Earlier this week, Bayer announced its regulatory success in the haemophilia field had prompted an internal restructure, which will see headcount in Berkely reduced by 227.

“Our transition into commercial production with three products has resulted in the need for organisational changes to enable these efficiencies,” ​a spokesperson told us in an emailed statement.

“The decision will not impact product availability as we remain committed to providing a portfolio of treatment options to serve the individual needs of the haemophilia community,” ​the spokesperson added.

In other restructuring news, earlier this year Bayer announced plans​ to transfer technology from a facility in Ansung, South Korea, to Berlin, and divested its prescription dermatology unit​ to Danish firm, LEO Pharma.

Related news

Show more

Related product

Process optimization for mAb commercial manufacturing

Process optimization for mAb commercial manufacturing

Content provided by Catalent | 01-Jun-2023 | Product Presentation

Process characterization and validation is an important step in the product development journey and late-phase development, and it is required before transferring...

Related suppliers